Pharma commercialisation outsourcing
Indegene provides digital-led commercialization services for the life sciences industry, including biopharmaceutical, emerging biotech and medical devices companies, that assist them with drug development and clinical trials, regulatory submissions, pharmacovigilance and complaints management, and the sales and marketing of their products. Its solutions enable life sciences companies to develop products, launch them in the market, and drive sales through their life cycle in a more effective, efficient and modern manner. It achieves this by combining over two decades of healthcare domain expertise and fit-for purpose technology.
Indegene Limited operates as a digital-first life sciences commercialization company in India, the United States, Europe, North America, and internationally. It operates through Enterprise Medical Solutions, Enterprise Commercial Solutions, and Other segments. The company provides AI-embedded commercialization services for biopharmaceutical, emerging biotech, and medical devices companies. It also offers enterprise commercial, medical, and clinical solutions; and omnichannel activation solutions. In addition, the company operates NEXT technology platforms, as well as provides analytics, technology, commercial, medical, regulatory, and safety services to life science and healthcare organizations. Further, it engages in the professional, and scientific and technical activities. Indegene Limited was incorporated in 1998 and is based in Bengaluru, India.
Key people: Mr. Manish Gupta (Executive Chairman & CEO) · Dr. Sanjay Suresh Parikh Ph.D. (Executive Director & Executive VP) · Mr. Suhas Prabhu ACA, BCom (Chief Financial Officer) · Mr. Anand Kiran Prafula Chandra Nijegal (Executive Vice President of Global Operations) · Mr. Tarun Mathur (Chief Technology Officer) · Abhishek Agarwal (Head of Investor Relations)
Indegene major competitors are Syngene Internatl., Jubilant Pharmova, Natco Pharma, Marksans Pharma, CORONA Remedies, Sudeep Pharma, Akums Drugs & Pharma. Market Cap of Indegene is ₹14,395 Crs. While the median market cap of its peers are ₹14,585 Crs.
Indegene seems to be less financially stable compared to its competitors.Altman Z score of Indegene is 8.58 and is ranked 4 out of its 8 competitors.
Yahoo profile 23 Sept 2026 · Tijori 23 Sept 2026
Latest reported mix as compiled by Tijori from company disclosures; percentages of revenue.
As the company reports them. They can differ from the ratio table on the Financials tab, which uses Tijori's own definitions (for example NIM on average total assets rather than on interest-earning assets); the Cross-check panel there lines both up.
Indegene is the only India-listed pure-play provider of technology-led commercialisation services to life-sciences companies (medical/regulatory writing, omnichannel marketing, pharmacovigilance, MLR review), serving all of the world's top-20 biopharma firms plus 105 active clients (65 at IPO). FY26 revenue Rs 3,510 cr (+23.6%); North America 75%, Europe 22%; ~60% of revenue is output/outcome-priced rather than hourly. It has bolted on BioPharm Communications (USD 104 mn, Oct-2025), Cake Kommunikations (EUR 8.5 mn, Nov-2025) and WARN & Co (2026).
TTM PE 34.3x on a margin-trough year (FY26 EBITDA margin 17.6% vs ~19.5% in FY24); stock ~19% below its 52-week high at end-Jul-2026. Listed only since May-2024, so no 5-yr history. EV/EBITDA computed on mcap less Rs 1,316 cr net cash over FY26 EBITDA. EV/EBITDA 20.9x; dividend yield 0.4%.
| Persistent Systems | Persistent grows at a similar ~23% but at a materially higher PE with generic-IT AI-deflation risk; Indegene grows faster in USD (26.5%) inside a regulated life-sciences niche at ~21x FY28E. |
| Sagility | Sagility is US-healthcare payer/provider BPO with single-digit organic growth and PE-sponsor overhang; Indegene sells to pharma commercial/medical budgets with 105 clients and 105.8% NRR. |
Share of revenue as disclosed in filings (Tijori normalisation). Segment profit measure: not disclosed in this source — segment EBIT/EBITDA/PBT are not shown rather than estimated. Eliminations and unallocated costs not available here.
Share of revenue as disclosed in filings (Tijori normalisation). Segment profit measure: not disclosed in this source — segment EBIT/EBITDA/PBT are not shown rather than estimated. Eliminations and unallocated costs not available here.
Share of revenue as disclosed in filings (Tijori normalisation). Segment profit measure: not disclosed in this source — segment EBIT/EBITDA/PBT are not shown rather than estimated. Eliminations and unallocated costs not available here.
Share of revenue as disclosed in filings (Tijori normalisation). Segment profit measure: not disclosed in this source — segment EBIT/EBITDA/PBT are not shown rather than estimated. Eliminations and unallocated costs not available here.
Info Tech — 6.5%: mostly not IT services
The internal "Info Tech" bucket holds four very different businesses and only one of them — Infosys, at 0.7% — is the tactical IT-services trade the house describes in its notes. That trade is deliberately small. Price a mature services company at zero terminal growth with 100% of profits paid out and an 8% required yield and the floor is about 12x earnings; the sector fell from roughly 30x toward that floor, which made a small dip worth buying. We see neither a case above 20x nor a collapse below 12x: a corridor of uncertainty held at 2–3% across the strategy, a position we expect to eventually exit. The reason the upside is capped is AI: the work does not go away (the back end of US banking still runs on 1970s books that must reconcile with new front ends) but far fewer people will be needed to do it. Infosys guides 1.5–3% constant-currency growth for FY27 with AI already 8% of revenue. The other three names are owned for entirely different reasons. Kaynes is electronics manufacturing — India's EMS market went from $10–12 bn in FY20 to $40–45 bn in FY25 and could exceed $150 bn by FY30 on the back of PLI, the ₹40,000 crore component scheme and import substitution. Paytm is a payments and lending platform in the world's largest real-time payment system (UPI: 24 bn transactions a month, +22%) whose regulator-inflicted crisis has passed. Indegene is a life-sciences commercialisation outsourcer riding the same $350 bn patent cliff as our pharma names — and its AI exposure is a tailwind, not a threat.
We do not own TCS, HCL Tech or Wipro because if we are going to hold a small tactical position in a sector with a capped upside we want the cheapest large franchise with the cleanest AI narrative — Infosys. Dixon (2.6–3% margins, PLI 1.0 expired, ROCE falling) is volume without value; Syrma and Amber are priced higher than Kaynes on trailing earnings with lower margins. PB Fintech is priced at 90x+ for an insurance-distribution model; Eternal is a quick-commerce cash-burn story we hold only in the AIFs. Persistent and Sagility lack Indegene's domain moat.